Moderna Says No Link Between COVID-19 Jab And Heart Inflammation
Moderna Inc (NASDAQ:MRNA) says there is no “causal association” between its COVID-19 vaccine and cases of myocarditis or pericarditis, based…
Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation
Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offering.
Zynerba’s Zygel Improves Sleep In Children With Severe Epilepsies
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE)…
Sanofi’s Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA Rejection
Sanofi SA’s (NASDAQ:SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold…
FDA Authorizes 10M JNJ COVID-19 Vaccine Doses, Asks To Discard 60M From Emergent Plant: NYT
The FDA has asked Johnson & Johnson (NYSE:JNJ) to discard 60 million doses of its COVID-19 vaccine manufactured at the…
Eli Lilly’s Internal Probe Clears Its COVID-19 Drug Plant; Memo Says Company Did Not Make False Statements: Reuters
Eli Lilly and Co (NYSE:LLY) revealed last month that the U.S. Department of Justice (DOJ) issued a subpoena into its manufacturing…
Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress
Aptose Biosciences Inc (NASDAQ:APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials – one in relapsed or…
Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease
Forma Therapeutics Holdings Inc (NASDAQ:FMTX) announced new data from its ongoing Phase 1 trial of etavopivat (FT-4202) in sickle cell disease.…
Protagonist Stock Moves Higher As Rusfertide Shows Durability Of Effect, Symptom Improvements In Blood Cancer Trial
Protagonist Therapeutics Inc (NASDAQ:PTGX) has announced updated results from the ongoing Phase 2 study of rusfertide for polycythemia vera (PV), a…
Chemomab Therapeutics Is Heating Up And Could See A Move Soon
Chemomab Therapeutics LTD. (NASDAQ: CMMB) shares are trading higher Friday as retail traders continue to push stocks higher.